Navigation Links
Kymab Announces Kymouse Antibody Discovery Agreement With Novo Nordisk

CAMBRIDGE, England, April 22, 2013 /PRNewswire/ --

Kymab, a monoclonal antibody biopharmaceutical company, announced today an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse™ human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases.

The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using these strains in combination, a diverse pool of human antibodies can be created with both classes of light chains fully represented.

Dr. Tom Shepherd , Chief Business Officer of Kymab, said: "Novo Nordisk's expertise and track record in developing biological therapeutics coupled with its existing therapeutic antibody discovery infrastructure makes it an ideal partner for Kymab. Our strategy is to partner the Kymouse platform broadly to maximise its potential in the discovery and development of new medicines."

Hanne Risager Romedahl, Vice President, Head of ImmunoTechnology, Novo Nordisk, said "Antibody therapeutics have great potential to advance patient care in diseases with significant unmet medical need.   Kymab's highly innovative and technically advanced Kymouse platform is an excellent fit with our existing therapeutic antibody discovery capability."

The financial terms of the agreement were not disclosed, but include platform licence fees,  development milestone payments for drug candidates and royalties on sales of antibodies discovered using the Kymouse strains.

About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.

Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.

Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development.

For further information, please visit

  About Novo Nordisk

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit

Kymab, Kymouse, Kymouse HK and Kymouse HL are trademarks of Kymab Limited.

Contact Kymab:

Dr. Tom Shepherd , Chief Business Officer
Tel: +44(0)1223-833301, Email:

M: Communications

Mary Clark
Tel: +44(0)20-7920-2361, Email:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:10/12/2015)... Paul, Minn. , Oct. 12, 2015 ... it, a need to help integrate these devices into ... leader of ergonomic healthcare mounting and mobility solutions, has ... its lightest cart yet, for a wide array of ... S-Tablet Cart SV10 was developed exclusively for Microsoft Surface ...
(Date:10/12/2015)... , Oct. 12, 2015  Today, Divurgent is honored ... Advisory Services. As a former CIO, Paul brings 15 years ... just understand or sympathize with today,s CIOs, he is one. ... same challenges Paul has faced, and his new role with ... ensuring technology efficiencies across an organization. ...
(Date:10/12/2015)... , Oct. 12, 2015   Royal Philips ... digitization of pathology, today announced a collaboration with ... world leading provider of genomic-based diagnostic tests, to leverage ... up of its molecular diagnostic testing processes.    ... the examination of patient tissue samples and plays a ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ActivePDF, a leading provider of ... to batch conversions of CAD drawings, plans, and diagrams to PDF that ... eliminates the complexity requirement of specialized applications to view CAD designs. Converting to ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... world’s first commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a significant ... Obstetrics in Vancouver, BC, Canada. , In a presentation entitled: "The ...
(Date:10/12/2015)... , ... October 13, 2015 , ... ... its biannual Heroes in Recovery Awards at Foundations Recovery Network’s Moments of Change ... presented the one-of-a-kind awards to Noah Levine and Dean Dauphinais who exemplify the ...
(Date:10/12/2015)... ... ... article published October 6th by the Herald Tribune, a recent study that compared ... 1988 has shown that it really is more difficult to lose weight these days. Specifically, ... 1971 would be on average 10 pounds heavier than their past counterpart. In terms of ...
(Date:10/12/2015)... ... ... Amerec , a leader in the steam and sauna industry, and ... displaying custom sauna and steam room solutions at the ISPA Conference & Expo in ... SpaEquip is recognized for their ability to assist in the design and implementation of ...
Breaking Medicine News(10 mins):